Aerie Pharmaceuticals has acquired the Spanish ophthalmic pharmaceutical company Avizorex Pharma, which is developing dry eye disease treatments, according to a press release.
Avizorex’s lead product candidate, AVX-012, contains a potent and selective agonist of the cold sensor and osmolarity sensor TRPM8 ion channel, which regulates ocular surface wetness and blink rate.
A phase 2a study of AVX-012 showed positive results supporting its therapeutic potential in treating the signs and symptoms of dry eye, the release said. Aerie plans to start a phase 2b study in late 2020.
“This
Uncategorized